Anaptysbio Stock Alpha and Beta Analysis
| ANAB Stock | USD 38.48 0.95 2.53% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as AnaptysBio. It also helps investors analyze the systematic and unsystematic risks associated with investing in AnaptysBio over a specified time horizon. Remember, high AnaptysBio's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to AnaptysBio's market risk premium analysis include:
Beta 1.39 | Alpha 0.68 | Risk 3.57 | Sharpe Ratio 0.23 | Expected Return 0.82 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
AnaptysBio |
AnaptysBio Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. AnaptysBio market risk premium is the additional return an investor will receive from holding AnaptysBio long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in AnaptysBio. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate AnaptysBio's performance over market.| α | 0.68 | β | 1.39 |
AnaptysBio expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of AnaptysBio's Buy-and-hold return. Our buy-and-hold chart shows how AnaptysBio performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.AnaptysBio Market Price Analysis
Market price analysis indicators help investors to evaluate how AnaptysBio stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading AnaptysBio shares will generate the highest return on investment. By understating and applying AnaptysBio stock market price indicators, traders can identify AnaptysBio position entry and exit signals to maximize returns.
AnaptysBio Return and Market Media
The median price of AnaptysBio for the period between Tue, Jun 25, 2024 and Mon, Sep 23, 2024 is 34.65 with a coefficient of variation of 15.26. The daily time series for the period is distributed with a sample standard deviation of 5.04, arithmetic mean of 32.99, and mean deviation of 4.12. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | AnaptysBio, Inc. Earnings Expected to Grow What to Know Ahead of Q4 Release - Yahoo Singapore News | 06/27/2024 |
2 | Allspring Global Investments Holdings LLC Purchases Shares of 1,688 AnaptysBio, Inc. - Defense World | 07/24/2024 |
3 | Illumina Expected to Beat Earnings Estimates Can the Stock Move Higher | 07/30/2024 |
4 | Despite currently being unprofitable, AnaptysBio has delivered a 78 percent return to shareholders over 1 year | 08/02/2024 |
5 | Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update | 08/05/2024 |
6 | Acquisition by Ecor1 Capital, Llc of 273972 shares of AnaptysBio at 36.5 subject to Rule 16b-3 | 08/14/2024 |
7 | AnaptysBio Top-Line AD Data End Of 2024 Could Be Turning Point - Seeking Alpha | 08/15/2024 |
8 | Anaptys Announces Participation in September Investor Conferences | 08/29/2024 |
9 | Disposition of 1300 shares by Orwin John A of AnaptysBio subject to Rule 16b-3 | 09/13/2024 |
10 | Disposition of 10000 shares by Dennis Mulroy of AnaptysBio at 40.13 subject to Rule 16b-3 | 09/16/2024 |
11 | Disposition of 3780 shares by Eric Loumeau of AnaptysBio at 38.4103 subject to Rule 16b-3 | 09/17/2024 |
12 | TANG CAPITAL MANAGEMENT LLC Acquires New Stake in Singular Genomics Systems Inc | 09/18/2024 |
About AnaptysBio Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including AnaptysBio or other stocks. Alpha measures the amount that position in AnaptysBio has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 (projected) | Days Sales Outstanding | 50.35 | 145.75 | 153.04 | PTB Ratio | 3.33 | 6.55 | 6.22 |
AnaptysBio Upcoming Company Events
As portrayed in its financial statements, the presentation of AnaptysBio's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, AnaptysBio's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of AnaptysBio's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of AnaptysBio. Please utilize our Beneish M Score to check the likelihood of AnaptysBio's management manipulating its earnings.
| 6th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 6th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with AnaptysBio
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Information and Resources on Investing in AnaptysBio Stock
When determining whether AnaptysBio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AnaptysBio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Anaptysbio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Anaptysbio Stock:Check out AnaptysBio Backtesting, AnaptysBio Valuation, AnaptysBio Correlation, AnaptysBio Hype Analysis, AnaptysBio Volatility, AnaptysBio History and analyze AnaptysBio Performance. For information on how to trade AnaptysBio Stock refer to our How to Trade AnaptysBio Stock guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
AnaptysBio technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.